Submit Content
Get the latest delivered to your inbox
Privacy Policy

Now Reading

Protecting Patients from Climate Risks: A Conversation with Frontline Health Clinics on Resources

Tuesday, December 6, 2022 | 12:30pm — 1:30pm EST

Protecting Patients from Climate Risks: A Conversation with Frontline Health Clinics on Resources

Tuesday, December 6, 2022 | 12:30pm — 1:30pm EST

Published 12-02-22

Submitted by Biogen

Climate Week with mountains and forest

After a year of more frequent climate-induced extreme weather, the Center for Climate, Health, and the Global Environment at Harvard T.H. Chan School of Public Health and Americares with support from Biogen have joined forces to release a new Climate Resilience for Frontline Clinics Toolkit to help community health centers and free clinics better manage care and protect patients in 2023.

Join a virtual launch event to hear firsthand from frontline health leaders about the climate risks they're experiencing on the ground and how new resources on extreme heat, wildfires, hurricanes, and floods can help clinics keep their patients healthy and make them more resilient to climate shocks.

Meet the Speakers

  • Ben Money | Senior Vice President for Public Health Priorities, National Association of Community Health Centers
  • Dr. Alexis Hodges | Nurse Practitioner, Community Care Clinic of Dare in Nags Head, NC
  • Kristin Stevens | Senior Director, Climate and Disaster Resilience, Americares
  • Opening remarks from Dr. Maha Radhakrishnan | Chief Medical Officer, Biogen
  • Moderated by Dr. Aaron Bernstein | Interim Director, Harvard Chan C-CHANGE

Biogen’s support for the program is part of Healthy Climate, Healthy Lives, the company’s groundbreaking 20-year, $250 million initiative to address climate, health and equity. The commitment aims to eliminate fossil fuel emissions across business operations by 2040, engage employees and suppliers, and collaborate with renowned institutions to advance the science and action to improve health outcomes.

RSVP here

Biogen Logo



At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology and pain. We routinely post information that may be important to investors on our website at To learn more, please visit and follow us on social media - Twitter, LinkedIn, Facebook, YouTube.

More from Biogen

Join today and get the latest delivered to your inbox